pRb controls estrogen receptor alpha protein stability and activity

Oncotarget

Volumn 4, Issue 6, 2013, Pages 875-883

  Caligiuri, Isabella ^a,b,c   Toffoli, Giuseppe ^c   Giordano, Antonio ^a,b   Rizzolio, Flavio ^a,c  

^a Temple University   (United States)

^b UNIVERSITY OF SIENA   (Italy)

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Breast cancer; Chaperone proteins; Estrogen receptor alpha; Prb; Proteasome

Indexed keywords

CHAPERONE; ESTROGEN RECEPTOR ALPHA; HEAT SHOCK PROTEIN 90; PROTEASOME; PROTEIN P23; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN;

AMINO TERMINAL SEQUENCE; ARTICLE; BREAST CANCER; CANCER CELL; CANCER PATIENT; HUMAN; HUMAN CELL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN STABILITY; REGULATORY MECHANISM; TREATMENT RESPONSE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; MCF-7 CELLS; MICE; MICE, KNOCKOUT; PROTEIN STABILITY; RECEPTOR CROSS-TALK; RETINOBLASTOMA PROTEIN; TUMOR CELLS, CULTURED;

EID: 84880845947     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1036     Document Type: Article

References (46)

1. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nature reviews. Cancer. 2009 Sep;9(9):631-43.
2. Bosco EE, Wang Y, Xu H, Zilfou JT, Knudsen KE, Aronow BJ, Lowe SW, Knudsen ES. The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. The Journal of clinical investigation. 2007 Jan;117(1):218-28.
3. Ertel A, Dean JL, Rui H, Liu C, Witkiewicz AK, Knudsen KE, Knudsen ES. RB-pathway disruption in breast cancer: differential association with disease subtypes, diseasespecific prognosis and therapeutic response. Cell cycle. 2010 Oct 15;9(20):4153-63.
4. Jiang Z, Deng T, Jones R, Li H, Herschkowitz JI, Liu JC, Weigman VJ, Tsao M-S, Lane TF, Perou CM, Zacksenhaus E. Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status. The Journal of clinical investigation. 2010 Sep;120(9):3296-309.
5. Rizzolio F, Lucchetti C, Caligiuri I, Marchesi I, Caputo M,Klein-Szanto AJ, Bagella L, Castronovo M, Giordano A. Retinoblastoma tumor-suppressor protein phosphorylation and inactivation depend on direct interaction with Pin1. Cell Death Differ. 2012 Jul;19(7):1152-61.
6. Viatour P, Sage J. Newly identified aspects of tumor suppression by RB. Dis Model Mech. 2011;4(5):581-5.
7. Derenzini M, Donati G, Mazzini G, Montanaro L, Vici M, Ceccarelli C, Santini D, Taffurelli M, Treré D. Loss of retinoblastoma tumor suppressor protein makes human breast cancer cells more sensitive to antimetabolite exposure. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Apr 1;14(7):2199-209.
8. Treré D, Brighenti E, Donati G, Ceccarelli C, Santini D, Taffurelli M, Montanaro L, Derenzini M. High prevalence of retinoblastoma protein loss in triple-negative breast cancers and its association with a good prognosis in patients treated with adjuvant chemotherapy. Annals of oncology. 2009 Nov;20(11):1818-23.
9. Dean JL, Thangavel C, McClendon AK, Reed CA, Knudsen ES. Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene. 2010 Jul 15;29(28):4018-32.
10. Stengel KR, Dean JL, Seeley SL, Mayhew CN, Knudsen ES. RB status governs differential sensitivity to cytotoxic and molecularly-targeted therapeutic agents. Cell cycle. 2008 Apr 15;7(8):1095-103.
11. Batsché E, Desroches J, Bilodeau S, Gauthier Y, Drouin J. Rb enhances p160/SRC coactivator-dependent activity of nuclear receptors and hormone responsiveness. The Journal of biological chemistry. 2005 May 20;280(20):19746-56.
12. Yeh S, Miyamoto H, Nishimura K, Kang H, Ludlow J, Hsiao P, Wang C, Su C, Chang C. Retinoblastoma, a tumor suppressor, is a coactivator for the androgen receptor in human prostate cancer DU145 cells. Biochemical and biophysical research communications. 1998 Jul 20;248(2):361-7.
13. Sharma A, Comstock CE, Knudsen ES, Cao KH, Hess-Wilson JK, Morey LM, Barrera J, Knudsen KE. Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells. Cancer Res. 2007;67(13):6192-203.
14. Rizzolio F, Esposito L, Muresu D, Fratamico R, Jaraha R, Caprioli GV, Giordano A. RB gene family: genome-wide ChIP approaches could open undiscovered roads. J Cell Biochem. 2010 Apr 1;109(5):839-43.
15. Caligiuri I, Rizzolio F, Boffo S, Giordano A, Toffoli G. Critical choices for modeling breast cancer in transgenic mouse models. J Cell Physiol. 2011 Aug;227(8):2988-91.
16. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J, Brodsky AS, Keeton EK, Fertuck KC, Hall GF, Wang Q, Bekiranov S, Sementchenko V, Fox EA, Silver PA, Gingeras TR, Liu XS, Brown M. Genome-wide analysis of estrogen receptor binding sites. Nat Genet. 2006;38(11):1289-97.
17. Macaluso M, Montanari M, Noto PB, Gregorio V, Bronner C, Giordano A. Epigenetic modulation of estrogen receptoralpha by pRb family proteins: a novel mechanism in breast cancer. Cancer research. 2007 Aug 15;67(16):7731-7.
18. Rizzolio F, Caligiuri I, Lucchetti C, Fratamico R, Tomei V, Gallo G, Agelan A, Ferrari G, Toffoli G, Klein-Szanto AJ, Giordano A. Dissecting Pin1 and phospho-pRb regulation. J Cell Physiol. 2012 May 2;
19. Leclercq G, Lacroix M, Laïos I, Laurent G. Estrogen receptor alpha: impact of ligands on intracellular shuttling and turnover rate in breast cancer cells. Current cancer drug targets. 2006 Feb;6(1):39-64.
20. Sherman MY. Proteotoxic stress targeted therapy (PSTT). Oncotarget. 2011 May;2(5):356-7.
21. Hildenbrand ZL, Molugu SK, Herrera N, Ramirez C, Xiao C, Bernal RA. Hsp90 can accommodate the simultaneous binding of the FKBP52 and HOP proteins. Oncotarget. 2(1- 2):43-58.
22. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nature reviews. Cancer. 2005 Oct;5(10):761-72.
23. Laïos I, Journé F, Nonclercq D, Vidal DS, Toillon R-A, Laurent G, Leclercq G. Role of the proteasome in the regulation of estrogen receptor alpha turnover and function in MCF-7 breast carcinoma cells. The Journal of steroid biochemistry and molecular biology. 2005 Mar;94(4):347- 59.
24. Tao YJ, Zheng W. Chaperones and the maturation of steroid hormone receptor complexes. Oncotarget. 2011 Mar;2(3):104-6.
25. Green KA, Carroll JS. Oestrogen-receptor-mediated transcription and the influence of co-factors and chromatin state. Nature reviews. Cancer. 2007 Sep;7(9):713-22.
26. Reid G, Hübner MR, Métivier R, Brand H, Denger S, Manu D, Beaudouin J, Ellenberg J, Gannon F. Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Molecular cell. 2003 Mar;11(3):695- 707.
27. Nonclercq D, Journé F, Laïos I, Chaboteaux C, Toillon R-A, Leclercq G, Laurent G. Effect of nuclear export inhibition on estrogen receptor regulation in breast cancer cells. Journal of molecular endocrinology. 2007 Aug;39(2):105- 18.
28. Kang KS, Morita I, Cruz A, Jeon YJ, Trosko JE, Chang CC. Expression of estrogen receptors in a normal human breast epithelial cell type with luminal and stem cell characteristics and its neoplastically transformed cell lines. Carcinogenesis. 1997 Feb;18(2):251-7.
29. Burns KA, Li Y, Arao Y, Petrovich RM, Korach KS. Selective mutations in estrogen receptor alpha D-domain alters nuclear translocation and non-estrogen response element gene regulatory mechanisms. The Journal of biological chemistry. 2011 Apr 8;286(14):12640-9.
30. Atsriku C, Britton DJ, Held JM, Schilling B, Scott GK, Gibson BW, Benz CC, Baldwin MA. Systematic mapping of posttranslational modifications in human estrogen receptor-alpha with emphasis on novel phosphorylation sites. Mol Cell Proteomics. 2009;8(3):467-80.
31. Sentis S, Le Romancer M, Bianchin C, Rostan MC, Corbo L. Sumoylation of the estrogen receptor alpha hinge region regulates its transcriptional activity. Mol Endocrinol. 2005;19(11):2671-84.
32. Berry NB, Fan M, Nephew KP. Estrogen receptoralpha hinge-region lysines 302 and 303 regulate receptor degradation by the proteasome. Molecular endocrinology. 2008 Jul;22(7):1535-51.
33. Burke JR, Deshong AJ, Pelton JG, Rubin SM. Phosphorylation-induced conformational changes in the retinoblastoma protein inhibit E2F transactivation domain binding. The Journal of biological chemistry. 2010 May 21;285(21):16286-93.
34. Ahlander J, Chen X-B, Bosco G. The N-terminal domain of the Drosophila retinoblastoma protein Rbf1 interacts with ORC and associates with chromatin in an E2F independent manner. PloS one. 2008 Jan;3(7):e2831.
35. Yang H, Williams BO, Hinds PW, Shih TS, Jacks T, Bronson RT, Livingston DM. Tumor suppression by a severely truncated species of retinoblastoma protein. Molecular and cellular biology. 2002 May;22(9):3103-10.
36. Campanero MR, Flemington EK. Regulation of E2F through ubiquitin-proteasome-dependent degradation: stabilization by the pRB tumor suppressor protein. Proceedings of the National Academy of Sciences of the United States of America. 1997 Mar 18;94(6):2221-6.
37. Hofmann F, Martelli F, Livingston DM, Wang Z. The retinoblastoma gene product protects E2F-1 from degradation by the ubiquitin-proteasome pathway. Genes & development. 1996 Dec 1;10(23):2949-59.
38. Kim Y-C, Kim SY, Mellado-Gil JM, Yadav H, Neidermyer W, Kamaraju AK, Rane SG. RB regulates pancreas development by stabilizing Pdx1. The EMBO journal. 2011 Apr 20;30(8):1563-76.
39. Lee MO, Kim EO, Kwon HJ, Kim YM, Kang HJ, Kang H, Lee JE. Radicicol represses the transcriptional function of the estrogen receptor by suppressing the stabilization of the receptor by heat shock protein 90. Molecular and cellular endocrinology. 2002 Feb 25;188(1-2):47-54.
40. Harris TJR, McCormick F. The molecular pathology of cancer. Nature reviews. Clinical oncology. 2010 May;7(5):251-65.
41. Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Journal of clinical oncology. 2010 Jun 1;28(16):2784-95.
42. Bosco EE, Knudsen ES. RB in breast cancer: at the crossroads of tumorigenesis and treatment. Cell cycle. 2007 Mar 15;6(6):667-71.
43. Subjeck JR, Repasky EA. Heat shock proteins and cancer therapy: the trail grows hotter! Oncotarget. 2011 Jun;2(6):433-4.
44. Adams JR, Schachter NF, Liu JC, Zacksenhaus E, Egan SE. Elevated PI3K signaling drives multiple breast cancer subtypes. Oncotarget. 2011 Jun;2(6):435-47.
45. Witkiewicz AK, Ertel A, McFalls J, Valsecchi ME, Schwartz G, Knudsen ES. RB-Pathway Disruption Is Associated with Improved Response to Neoadjuvant Chemotherapy in Breast Cancer. Clinical cancer research. 2012 Sep 15;18(18):5110-22.
46. Rizzolio F, Bione S, Sala C, Tribioli C, Ciccone R, Zuffardi O, Di Iorgi N, Maghnie M, Toniolo D. Highly conserved non-coding sequences and the 18q critical region for short stature: a common mechanism of disease? PLoS One. 2008 Jan;3(1):e1460.